A study published in the New England Journal of Medicine has found that remdesivir - the Gilead Sciences drug authorized to treat COVID-19 - is chiefly helpful to those on supplemental oxygen, rather than patients who progress to requiring a ventilator or extracorporeal membrane oxygenation.
Osimertinib (OSI), also known as AZD9291, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has been approved for the treatment of non-small cell lung cancer ...